Download presentation
Presentation is loading. Please wait.
Published byJoanna Allison Modified over 9 years ago
1
November 11, 2010
8
Undernutrition
10
61/2 m/o ex 34 WGA twins with: FTT Severe Global Developmental Delay Hypertonia Oculomotor findings Reflux Intermittent Diarrhea HSM h/o neutropenia and thrombocytopenia
12
Gaucher Disease Inborn error of metabolism Affects recycling of cellular glycolipids Defect in -glucocerebrosidase Accumulation of glucocerebroside in lysosomes Most common lysosomal storage disease Incidence 1/75,000 worldwide Autosomal recessive
13
Clinical Presentation Neurologic dysfunction Developmental Delay Oculomotor dysfunction Pathologic fractures Hepatosplenomegaly Anemia Neutropenia Thrombocytopenia Cardiac and renal symptoms typically absent
14
Gaucher Disease Ashkenazi Jews 7% heterozygous Frequency of disease 1:1000 Also common among Swedish
15
Diagnosis Gaucher cells in bone marrow False negatives Gold Standard: Enzyme assay ( -glucocerebrosidase) Molecular DNA analysis Carrier testing recommended for close relatives
16
Three Clinical Types
17
Type 1 Adult onset Most common Most closely tied with Ashkenazi Jews NO CNS findings Varies from mild to severe Enzyme replacement: near-normal life expectancy
18
Type 2 Most severe form Death by age 2 Treatment usually not indicated Early, severe CNS involvement Brainstem abnormalities
19
Type 3 Juvenile onset “chronic/subacute form” Most common in Swedish Later onset: Incoordination, mental deterioration, seizures Slowly progressive Becomes severe in later childhood
20
Treatment Enzyme replacement therapy Glucocerebrosidase IV Some improvement within 6 months Not effective for CNS symptoms Research Oral therapy Gene therapy
22
Lysosomal Storage Diseases Mutation in gene coding for production of lysosomal enzymes Accumulation of substrate Impairment of cell function >40 different LSD Start in late infancy or early childhood with slowly progressive symptoms
23
Lysosomal Storage Diseases Mucopolysaccharides Hurler’s Hunter’s Sanfilippo Morquio Glycolipids Gaucher Fabry Krabbe Tay Sachs
24
Lysosomal Storage Diseases Mucopolysaccharidoses Cannot break down glycosaminoglycans Clinical effects Coarsening of facial features Skeletal abnormailities Dysostosis multiplex Joint structure and function Organomegaly +/- Cognitive abilities +/- Corneal clouding Treatment: enzyme replacement or BMT
25
DiseaseDescriptionInheritance Hurler’s (MPS I)+ corneal clouding + developmental regression AR Hunter’s (MPS II)no corneal clouding + developmental regression X-linked Sanfilippo (MPS III)no corneal clouding + developmental regression AR Morquiro (MPS IV)+ corneal clouding * Normal intelligence AR
26
Lysosomal Storage Diseases Sphingolipidoses Developmental regression Organomegaly Cherry red macula Bone pain Short
27
DiseaseDescription GaucherHSM, bone pain, easy bruisibility FabryOrange-colored skin lesions, opacities of the eye, vascular disease (heart, brain, kidney) KrabbeDemyelination and progressive neuro deterioration Tay SachsNo HSM, cherry red spot, neuro deterioration Niemann-PickHSM, cherry red spot, peripheral neuropathy
28
Glycogen Storage Disease Von Gierke Disease (GSD I) Liver can’t produce glucose Features Hypoglycemia with prolonged fasting Organomegaly Cherubic face Poor growth Elevated TG and cholesterol Lab findings Elevated lactic and uric acid Treatment Frequent snacks and meals
29
Glycogen Storage Disease Pompe Disease (GSD II) Cannot use muscle glycogen Features Muscle weakness Muscles are hard Rhabdomyolysis FTT Macroglossia Cardiomegaly Treatment Enzyme replacement
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.